Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer
Anas Taha,
Stephanie Taha-Mehlitz,
Stephanie Petzold,
Sergey L. Achinovich,
Dmitry Zinovkin,
Bassey Enodien,
Md Zahidul I. Pranjol,
Eldar A. Nadyrov
Affiliations
Anas Taha
Department of Surgery, GZO Hospital, 8620 Wetzikon, Switzerland
Stephanie Taha-Mehlitz
Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, 4002 Basel, Switzerland
Stephanie Petzold
Faculty of Medicine, Eberhard-Karls-University, 72074 Tübingen, Germany
Sergey L. Achinovich
Department of Pathology, Gomel State Medical University, 211657 Gomel, Belarus
Dmitry Zinovkin
Department of Pathology, Gomel State Medical University, 211657 Gomel, Belarus
Bassey Enodien
Department of Surgery, GZO Hospital, 8620 Wetzikon, Switzerland
Md Zahidul I. Pranjol
School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK
Eldar A. Nadyrov
Department of Pathology, Gomel State Medical University, 211657 Gomel, Belarus
The aim of this study is to reveal the potential roles of apoptosis markers (Bcl2 and p53), proliferation markers (Ki-67 and CyclD1), and the neuroendocrine marker Chromogranin A as markers for the radioresistance of rectal cancer. Statistically significant differences were found in the expression of p53, Ki-67, and Chromogranin A in groups of patients with and without a favorable prognosis after radiotherapy. The survival analysis revealed that the marker of neuroendocrine differentiation, Chromogranin A, also demonstrated a high prognostic significance, indicating a poor prognosis. Markers of proliferation and apoptosis had no prognostic value for patients who received preoperative radiotherapy. Higher Chromogranin A values were predictors of poor prognosis. The results obtained from studying the Chromogranin A expression suggest that the secretion of biologically active substances by neuroendocrine cells causes an increase in tumor aggressiveness.
